Pfizer’s Lung Cancer Drug Fails to Meet Goals in Phase 3 Trials
Pfizer Inc. (NYSE:PFE) announced Monday that it’s lung cancer drug, which has been undergoing phase 3 studies, failed to meet its objectives for the studies, according to the Wall Street Journal. The drug, which is called dacomitinib, was developed to treat nonsmall cell lung cancer in patients who have already been treated for the same condition, including patients treated with chemotherapy (second and third line.)
The phase 3 trials of the treatment have involved three different studies. In the first, dacomitinib failed to demonstrate statistically significant improvement toward progression-free survival as compared to an existing cancer drug, erlotinib. In the second, the drug failed to prolong overall survival versus a placebo in patients previously treated with the standard therapy: chemotherapy and a tyrosine kinase inhibitor.
The third trial is underway, and is evaluating the drug’s effectiveness in another, different population of patients who are what’s called treatment-naive, or without prior treatment. This third study will be comparing decomitinib’s effectiveness to that of another drug, gefitinib. The results of that trial will not be available until next year, according to Pfizer.